Expanding the Use of SGLT2 Inhibitors in T2D Patients Across Clinical Settings

Expanding the Use of SGLT2 Inhibitors in T2D Patients Across Clinical Settings

Sodium-glucose cotransporter-2 inhibitors (SGLT2i) are currently recommended in patients with type 2 diabetes (T2D) to reduce serum glucose levels. Moreover, robust evidence has clearly demonstrated their beneficial cardiovascular and renal effects, making this class of drugs pivotal for the treatme...

Full description

Saved in:
Bibliographic Details
Main Authors: Alessandro Cuttone, Vittorio Cannavò, Raouf Mastan Sheik Abdullah, Pierluigi Fugazzotto, Giada Arena, Simona Brancati, Andrea Muscarà, Carmela Morace, Cristina Quartarone, Domenica Ruggeri, Giovanni Squadrito, Giuseppina Tiziana Russo
Format: Article
Language:English
Published: MDPI AG 2025-05-01
Series:Cells
Subjects:
SGLT2i
T2D
CVOTs
cardiovascular effects
renal effects
bone metabolism
Online Access:https://www.mdpi.com/2073-4409/14/9/668
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.mdpi.com/2073-4409/14/9/668

Similar Items